Unlock your academic potential and expand your network by joining us!
Prof. Dr. Klaus Kopka is a radiopharmaceutical chemist and holds a full professorship for Bioinorganic and Radiopharmaceutical Chemistry at TU Dresden, Germany, combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR]. Between 2013 and 2019, he held a full professorship at Ruprecht-Karls-University of Heidelberg, Germany. At the same time, he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in Heidelberg. He was involved in the development of theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e. PSMA-617 (approved as Pluvicto), and PSMA-1007 (approved as Radelumin). Prof. Kopka is a guest editor of several MDPI special issues, "Radiopharmaceutical Chemistry between Imaging and Radioendotherapy", “Emerging Theranostic Tracers in the Context of Radiopharmaceutical Drug Development”, “Forward Thinking towards Theranostic (Radio)ligands Targeting the Tumor Microenvironment (TME)”, and “Feature Reviews in Radiopharmaceutical Sciences: Highlights of Two-Decade Development”. His research interests are radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide theranostics; targeted endoradiotherapy; and noninvasive molecular PET and SPECT imaging. His scientific output includes 257 publications, corresponding to 12,132 citations (h-index 55) (Scopus, 26-Dec-2023).
Prof. Dr. Klaus Kopka is a radiopharmaceutical chemist and holds a full professorship for Bioinorganic and Radiopharmaceutical Chemistry at TU Dresden, Germany, combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR]. Between 2013 and 2019, he held a full professorship at Ruprecht-Karls-University of Heidelberg, Germany. At the same time, he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in Heidelberg. He was involved in the development of theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e. PSMA-617 (approved as Pluvicto), and PSMA-1007 (approved as Radelumin). Prof. Kopka is a guest editor of several MDPI special issues, "Radiopharmaceutical Chemistry between Imaging and Radioendotherapy", “Emerging Theranostic Tracers in the Context of Radiopharmaceutical Drug Development”, “Forward Thinking towards Theranostic (Radio)ligands Targeting the Tumor Microenvironment (TME)”, and “Feature Reviews in Radiopharmaceutical Sciences: Highlights of Two-Decade Development”. His research interests are radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide theranostics; targeted endoradiotherapy; and noninvasive molecular PET and SPECT imaging. His scientific output includes 257 publications, corresponding to 12,132 citations (h-index 55) (Scopus, 26-Dec-2023).
You can be the first follower.
